N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease.

导出 LinkOut

翻译打印收藏纠错

作者： Jianan,Guo ^[1] ; Yujia,Zhang ^[1] ; Changjun,Zhang ^[2] ; Chuansheng,Yao ^[1] ; Jingqi,Zhang ^[1] ; Xiaoying,Jiang ^[3] ; Zhichao,Zhong ^[1] ; Jiamin,Ge ^[1] ; Tao,Zhou ^[4] ; Renren,Bai ^[5] ; Yuanyuan,Xie ^[6]

作者单位： College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China. ^[1] Collaborative Innovation Centre of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, PR China. ^[2] College of Material Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou, PR China. ^[3] School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, PR China. ^[4] College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, PR China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, PR China. Electronic address: renrenbai@126.com. ^[5] College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China; Collaborative Innovation Centre of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, PR China. Electronic address: xyycz@zjut.edu.cn. ^[6]

关键词 Alzheimer’s disease Hydroxypyridinone Iron-chelating Monoamine oxidase B Multitarget-directed ligands N-Propargylamine